[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339431-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339431-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-subtyping-improves-breast-cancer-diagnosis-in-the-copenhagen-breast-cancer-genomics-study","Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study","","Intrinsic molecular subtypes define distinct biological forms of breast cancer and can refine diagnosis and risk allocation. The Copenhagen Breast Cancer Genomics Study prospectively enrolled women diagnosed between 2014 and 2021, using CIT256 and PAM50 molecular profiling for primary invasive tumors without prior malignancy. Among 2,816 patients, molecular subtyping increased nonluminal subtypes across stages I to IV and showed significant survival differences. Discordant subtype calls between CIT256 and IHC predicted death risk in IHC luminal cancers, highlighting the clinical importance of accurate subtype assessment in high-risk patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-subtyping-improves-breast-cancer-diagnosis-in-the-copenhagen-breast-cancer-genomics-study/339431/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-subtyping-improves-breast-cancer-diagnosis-in-the-copenhagen-breast-cancer-genomics-study/339431.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of molecular subtyping in this study?","Question",{"text":63,"@type":64},"To define intrinsic molecular subtypes that characterize biologic breast cancers and improve diagnosis and risk allocation beyond traditional clinical staging and receptor expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients and tumors profiled in the Copenhagen Breast Cancer Genomics Study?",{"text":68,"@type":64},"Women diagnosed at Rigshospitalet from 2014 to 2021 were included, and eligible patients received molecular profiling using the CIT256 and PAM50 molecular profiles for primary invasive breast cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about survival differences and subtype discordance?",{"text":72,"@type":64},"Survival differed significantly among molecular subtypes across stages. Discordant subtype results between CIT256 and IHC occurred in 442 tumors and were associated with increased death risk among patients with IHC luminal breast cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339431,1790193306,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","CLINIC AL  \nMEDICINE  \nConflict of interest: TB has institutional grants from Pfizer, Astra Zeneca, Novartis, Samsung Bioepis, Seattle Genetics, Merck, Eli Lilly, and Daiichi Sankyo. TB was on the advisory board for Novartis and has traveled for Daiichi Sankyo. MJ was on the advisory board for Novartis. ASK has institutional grants from Pfizer, AstraZeneca, Merck, Eli Lilly, Seattle Genetics, Roche, and Novartis and has personal grants from Astra Zeneca (travel and advisory board), MSD (travel), Daiichi Sankyo (advisory board), Novartis (advisory board), Seagen (advisory board), and Gilead (advisory board) . BE has institutional grants from:Astra Zeneca, Daiichi Sankyo, Eli Lilly, Merck, Novartis, and Pfizer; was on the advisory board for Eli Lilly and Medac; and has traveled for Daiichi Sankyo and Merck. MR was on the advisory board for Merck; has conducted talks for Merck and GSK; and has an institutional grant from Astra Zeneca.  \nCopyright: © 2024, Berg et al. This isan open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: November 30, 2023  \nAccepted: February 16, 2024  \nPublished: April 8, 2024  \nReference information: JCI Insight. 2024;9(7):e178114 .  \n[https://doi.org/10.1172/jci](https://doi.org/10.1172/jci).  \ninsight.178114 .  \nMolecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study  \nTobias Berg,1,2,3 Maj-Britt Jensen,1 Alan Celik,1 Maj-Lis Talman,4 Maria Anna Misiakou,3 Ann Søegaard Knoop,1,2 Finn Cilius Nielsen,3,5 Bent Ejlertsen,1,2,5 and Maria Rossing3,5  \n1Danish Breast Cancer Group, 2Department of Clinical Oncology, 3Center for Genomic Medicine, and 4Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 5Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.  \nBACKGROUND. Intrinsic molecular subtypes define distinct biological breast cancers and can be used to further improve diagnosis and risk allocation.  \nMETHODS. The Copenhagen Breast Cancer Genomics Study (CBCGS) prospectively included women diagnosed with breast cancer at Rigshospitalet from 2014 to 2021. Eligible patients were females with a primary invasive breast cancer (T1c, if N0M0; otherwise, any T, any N, or any M stage) and no prior malignancy. All patients underwent molecular profiling with the CIT256 and PAM50 molecular profile.  \nRESULTS. In the study period, 2,816 patients were included in the CBCGS. Molecular subtyping showed an increase in nonluminal (molecular-apocrine, luminal C, and Basal-like) as compared with luminal (luminal A, luminal B, and Normal-like) subtypes with increasing stage from I to IV. Across all stages, we found a significant difference in survival among subtypes; 91% of patients with LumA were alive at 5 years compared with 91% for LumB, 84% for LumC, 82% for mApo, and 80% for Basal-like. We identified 442 tumors (16%) that were discordant in subtype between CIT256 and IHC. Discordant subtype proved to be a risk factor of death among patients with IHC luminal breast cancer (hazard ratio [HR], 2.08; 95% CI, 1.51–2.86) in a multivariable Cox regression analysis. Discordance occurred more often among patients with N3, stage IV, or grade III disease.  \nCONCLUSION. Our findings indicate that molecular subtypes are a predominant classification for survival. Assessment is particularly crucial for patients with IHC luminal breast cancer with known high-risk factors, since they are at an increased risk of harboring an aggressive molecular subtype.  \nIntroduction  \nIntrinsic molecular subtypes of breast cancer are biologic entities associated with specific prognostic and therapeutic features and provide further prognostic information than traditional clinical assessment with staging and receptor expression (1–3) . Of the original 5 intrinsic subtypes,(Luminal A, Luminal B, HER2-enriched, Basal-like, and Normal-like) commercially available platforms have ","cbCaig3VmuB1MldV","https://ap.wps.com/l/cbCaig3VmuB1MldV","pdf",661034,12,"English","# Background\n# Methods\n# Results\n# Conclusion\n## Introduction","[{\"question\":\"What is the purpose of molecular subtyping in this study?\",\"answer\":\"To define intrinsic molecular subtypes that characterize biologic breast cancers and improve diagnosis and risk allocation beyond traditional clinical staging and receptor expression.\"},{\"question\":\"How were patients and tumors profiled in the Copenhagen Breast Cancer Genomics Study?\",\"answer\":\"Women diagnosed at Rigshospitalet from 2014 to 2021 were included, and eligible patients received molecular profiling using the CIT256 and PAM50 molecular profiles for primary invasive breast cancer.\"},{\"question\":\"What did the study find about survival differences and subtype discordance?\",\"answer\":\"Survival differed significantly among molecular subtypes across stages. Discordant subtype results between CIT256 and IHC occurred in 442 tumors and were associated with increased death risk among patients with IHC luminal breast cancer.\"}]","Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study | PDF",1790030263,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfaeadb808de7ea0218c6892751fd8cc.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ea13ec874a568327f2ffe4bfc08776a.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3fe6a6c03329c41a7f8fcc37c51ade05.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49b9577b7b5916e920bb4b374e67cbaf.webp",980,1311]